Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ECULIZUMAB Cause Systemic inflammatory response syndrome? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Systemic inflammatory response syndrome have been filed in association with ECULIZUMAB (SOLIRIS). This represents 0.0% of all adverse event reports for ECULIZUMAB.

11
Reports of Systemic inflammatory response syndrome with ECULIZUMAB
0.0%
of all ECULIZUMAB reports
2
Deaths
9
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From ECULIZUMAB?

Of the 11 reports, 2 (18.2%) resulted in death, 9 (81.8%) required hospitalization, and 1 (9.1%) were considered life-threatening.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ECULIZUMAB. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does ECULIZUMAB Cause?

Fatigue (4,858) Off label use (4,228) Haemoglobin decreased (3,028) Headache (2,699) Death (2,221) Pyrexia (1,948) Dyspnoea (1,819) Asthenia (1,732) Drug ineffective (1,644) Nausea (1,579)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which ECULIZUMAB Alternatives Have Lower Systemic inflammatory response syndrome Risk?

ECULIZUMAB vs EDARAVONE ECULIZUMAB vs EDETATE ECULIZUMAB vs EDOXABAN ECULIZUMAB vs EDOXABAN TOSILATE ECULIZUMAB vs EFALIZUMAB

Related Pages

ECULIZUMAB Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome ECULIZUMAB Demographics